Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Uğur Özkerim
Observed names:
U. Ozkerim,
Ugur OZKERIM,
Ugur Ozkerim,
Ugur Ozkeri̇m,
Uğur ÖZKERİM
Institutions:
Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi,
Sağlık Bilimleri Üniversitesi
Observed institutions:
Izmir Kâtip Çelebi University,
Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi,
Sağlık Bilimleri Üniversitesi
ORCID:
0000-0001-8527-1392
Observed ORCID:
0000-0001-8527-1392
OpenAlex ID:
A5066196790
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy
2024
·
Sedat Yildirim
, Akif Dogan
, et al.
·
Scientific Reports
·
30
Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
2023
·
Hatice Odabas
, Akif Dogan
, et al.
·
Medicina
·
16
PDF
Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer
2025
·
Oğuzcan Kınıkoğlu
, Yunus Emre Altıntaş
, et al.
·
The Oncologist
·
12
Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status
2024
·
Goncagul Akdag
, Sedat Yildirim
, et al.
·
Chemotherapy
·
10
Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage
2025
·
Tugba Basoglu
, Ugur Ozkerim
, et al.
·
Journal of Clinical Medicine
·
7
PDF
Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study
2025
·
Ugur Ozkerim
, Deniz Isik
, et al.
·
Journal of Personalized Medicine
·
5
PDF
Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma
2026
·
Sila Oksuz
, Oguzcan Kinikoglu
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
4
PDF
Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide
2026
·
Ugur Ozkerim
, Oguzcan Kinikoglu
, et al.
·
Journal of Clinical Medicine
·
3
PDF
Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
2025
·
Heves Surmeli
, Sedat Yıldırım
, et al.
·
Medicina
·
3
PDF
Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis
2026
·
Sila Oksuz
, Oguzcan Kinikoglu
, et al.
·
Journal of Clinical Medicine
·
2
PDF
Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine
2025
·
Sila Oksuz
, Oguzcan Kinikoglu
, et al.
·
Medicina
·
2
PDF
Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression
2024
·
Yunus Emre Altıntaş
, Oğuzcan Kınıkoğlu
, et al.
·
Medicina
·
2
PDF
Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study
2026
·
Ugur Ozkerim
, Oguzcan Kinikoglu
, et al.
·
Medicina
·
1
PDF
Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy
2025
·
Yunus Emre Altıntaş
, Oğuzcan Kınıkoğlu
, et al.
·
Current Oncology
·
1
PDF
Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer
2025
·
Heves Surmeli
, Deniz Isik
, et al.
·
Pharmaceuticals
·
1
PDF
Very Favorable vs. Favorable Risk Groups in Metastatic Renal Cell Carcinoma: A Step Toward Personalized Treatment
2025
·
Yunus Emre Altıntaş
, Oğuzcan Kınıkoğlu
, et al.
·
Cancers
·
1
The association of hemoglobin/red blood distribution width with overall survival: a retrospective analysis of melanoma
2023
·
Goncagul AKDAG
, Ozlem N. SEVER
, et al.
·
Esperienze Dermatologiche
·
1
FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval
2026
·
Ugur Ozkerim
, Oguzcan Kınıkoglu
, et al.
·
Cancers
Pan‑immune‑inflammation value as a prognostic and predictive biomarker in metastatic non‑small cell lung cancer treated with nivolumab: A real‑world study
2026
·
Nedi̇m Turan
, Hacer Yildiz
, et al.
·
Oncology Letters
PDF
105P HER2 amplification drives resistance to anti-EGFR therapy in RAS/BRAF wild-type metastatic colorectal cancer: A real-world study
2026
·
U. Ozkerim
, O. Kinikoglu
·
Annals of Oncology
PDF
Impact of Post-chemotherapy Radiotherapy on Survival Outcomes in Inoperable Malignant Mesothelioma: A Single-center Retrospective Analysis
2026
·
Sıla ÖKSÜZ
, Uğur ÖZKERİM
, et al.
·
Journal of Oncological Sciences
PDF
Pneumococcal Vaccination in Oncology Practice in Türkiye: Results of Patient and Physician Survey Studies
2026
·
Uğur Özkerim
, Sıla Öksüz
·
Cerrahpasa Medical Journal
PDF
486P Machine learning–based prediction of nivolumab response using systemic inflammatory biomarkers in advanced NSCLC: A real-world study
2026
·
U. Ozkerim
, O. Kinikoglu
·
ESMO Open
Prognostic Impact of Immune-Related Adverse Events in Patients with Non–Small Cell Lung Cancer Treated with Second-Line Nivolumab: A Single-Center Real-World Experience
2026
·
Uğur Özkerim
, Sıla Öksüz
, et al.
·
Eurasian Journal of Medical Investigation
The Comparison of Myocardial Dysfunction Using Speckle Tracking Echocardiography in Resistive and Non-Resistive Familial Mediterranean Fever Patients
2026
·
Ugur Ozkerim
, Hasan Kocaayan
, et al.
·
Southern Clinics of Istanbul Eurasia
PDF
Show more works
View as search
Works count:
29
Citation count:
101
H-index:
5
I10-index:
4
Year
Topic
Type